Nexavar (Sorafenib)

Sorafenib, the active ingredient in Nexavar, is a multikinase inhibitor presented as a 200 mg oral tablet for oral use. It treats advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and radioiodine‑refractory differentiated thyroid carcinoma in adult patients.

GNH USA supplies Nexavar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nexavar (sorafenib) is indicated for malignancies driven by angiogenesis and cell‑proliferation pathways. - Advanced renal cell carcinoma: improves progression‑free survival in adults with metastatic disease. - Unresectable hepatocellular carcinoma: slows tumor growth in patients not eligible for surgery or locoregional therapy. - Radioiodine‑refractory differentiated thyroid carcinoma: extends disease control in patients with progressive disease.

Sorafenib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hand‑foot skin reaction: redness, swelling, or pain on palms and soles. - Diarrhea: frequent loose stools. - Fatigue: persistent tiredness. - Hypertension: elevated blood pressure.

Serious or Rare Side Effects: - Cardiac ischemia or infarction: chest pain or heart attack symptoms. - Severe hepatic dysfunction: jaundice, markedly elevated liver enzymes. - Hemorrhage: bleeding events, including gastrointestinal bleeding.

Before initiating sorafenib therapy, several precautions should be considered. - Cardiovascular monitoring: assess blood pressure and cardiac status regularly. - Hepatic function: evaluate liver enzymes before and during treatment. - Dermatologic assessment: monitor for severe hand‑foot skin reaction and skin lesions. - Pregnancy risk: avoid use in pregnancy; drug is category D. - Drug interactions: review concomitant medications for potential CYP3A4 interactions. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Sorafenib can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce sorafenib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase sorafenib levels and toxicity. - Anticoagulants (e.g., warfarin): increased bleeding risk.

Moderate Interactions (Monitor Closely): - Antihypertensives: sorafenib may exacerbate hypertension, requiring dose adjustment. - QT‑prolonging agents: combined use may increase risk of cardiac arrhythmias. - St. John’s wort: may lower sorafenib concentrations.